Schwan: Roche to pursue 'targeted acquisitions'

Roche isn't pursuing any large deals, especially ones the size of Abbott Labs' ($ABT) recently announced overhaul, CEO Severin Schwan (photo) said in an interview. "We are not interested in mega-mergers. We are interested in very targeted acquisitions which complement our technologies and portfolios," he explained. News

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.